tbuckley/cabot-search huggingface dataset:
Torticollis in Infancy and Childhood. Sternomastoid Fibrosis and the Sternomastoid "Tumour."
Authors: Peter G. Jones
Journal: Annals of Internal Medicine (1968)

child as well as respect for other beings, whereas the death of the animal is not solely a tragedy but also an opportunity for the child to grow in maturity. The book is divided by age groups from babies through 5 year olds. In each section the activities range from the relatively pas¬ sive to the rambunctiously active with sug¬ gestions for indoors and out, the sick and regressing child as well as the hostile, ag¬ gressive, or hyperactive child. A most re¬ freshing few paragraphs are on Tearing, Ripping, and Punching—an utterly original subject but one most apropos for 3-, 4-, or 5-year-old boys cooped up on a rainy after¬ noon. The drawings byMarc Simont are truly charming and very reminiscent of A. A. Milne. This reviewer found the book refreshing and instructive even for the experienced pediatrician, ideal for the office waiting room, but even more so for the bedside of every mother of a child under 6. Young pediatricians studying for their Board exams could learn a considerable amount of growth and development, improve their techniques for dealing with children, and have a thoroughly enjoyable evening reading this brief volume. HUGO DUNLAP SMITH, MD Cincinnati
MYCOTIC ANEURYSM; REPORT OF ONE CASE
Authors: Vincent William Koch, Thomas Ochsner Nuzum
Journal: Annals of Internal Medicine (1940)

Case Reports1 September 1940MYCOTIC ANEURYSM; REPORT OF ONE CASEVINCENT WILLIAM KOCH, M.D., F.A.C.P., THOMAS OCHSNER NUZUM, M.D.VINCENT WILLIAM KOCH, M.D., F.A.C.P.Search for more papers by this author, THOMAS OCHSNER NUZUM, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-3-522 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCASE REPORTR. C., a white male, 43 years of age, was seen on December 10, 1935, complaining that for two days he had been having severe head pain in the right frontal area. He had been ailing since August 1935, when he had developed cerebro-spinal meningitis. At that time he had been treated by spinal drainage and instillation of four doses of serum. He had recovered in four weeks, but had continued to feel very weak. About October 1 he began to feel pain in his joints, particularly in the knees and hips, and running down into his feet....Bibliography1. LENSTHATCHER RDHS: Mycotic aneurysms, Arch. Int. Med., 1926, xxxviii, 226. Google Scholar2. REIFENSTEIN BW: Two cases of mycotic aneurysm, gonococcal and pneumococcal in origin, Am. Jr. Med. Sci., 1924, clxviii, 381-388. CrossrefGoogle Scholar3. OSLER W: Modern medicine, 1908, Lea & Febiger, 455, 545. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: VINCENT WILLIAM KOCH, M.D., F.A.C.P.; THOMAS OCHSNER NUZUM, M.D.Affiliations: Janesville, Wisconsin*Received for publication March 21, 1940. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Behandlung der sackförmigen intrakraniellen AneurysmenSUBACUTE BACTERIAL ENDOCARDITIS PRESENTING AS A SUBARACHNOID HEMORRHAGE: REPORT OF A CASE WITH RECOVERY*ROBERT L. WHIPPLE JR., M.D., F.A.C.P. 1 September 1940Volume 14, Issue 3 Page: 522-528 Keywords Aneurysms Arthralgia Hip Knees Meningitis Running ePublished: 1 December 2008 Issue Published: 1 September 1940 PDF downloadLoading ...
Abstract P383: Possible Effect Modification of Beta-Blockers on the Association Between Heart Failure and Fracture Risk: A Cohort Study
Authors: Yariv Gerber, Veronique L Roger, L. Joseph Melton, Susan A Weston, Shannon M Dunlay, Alanna M Chamberlain, Ruoxiang Jiang, Sheila M McNallan, Shreyasee Amin
Journal: Circulation (2014)

Introduction: Heart failure (HF) is a chronic illness that occurs within a context of multiple comorbidities, including osteoporosis and fractures. While the causal pathway leading to elevated fracture risk in HF has yet to be determined, a potential mechanism may be increased sympathetic activation that inhibits bone formation and enhances resorption. By antagonizing sympathetic tone, β-blockers may protect against bone loss and, thereby, fractures. We assessed the association of HF with subsequent osteoporotic fractures by β-blocker use in a community setting. Methods: Olmsted County, Minnesota, residents meeting Framingham criteria for incident HF from 1990-2002 and community controls without HF, who were matched (1:1) to cases on age, sex, and index year, were studied using the resources of the Rochester Epidemiology Project. Major osteoporotic fracture (proximal femur, lumbar/thoracic vertebrae, distal forearm, or proximal humerus) risk in HF was compared directly with that in their matched controls utilizing a stratified Cox model with the case/control pairs forming the strata. Death as a competing risk was accounted for using the Fine &amp; Gray model. Results: Among 1,050 participants (50% women; 525 with HF and 525 controls) 229 developed osteoporotic fractures during a mean follow-up of 6 years. The incidence rates of osteoporotic fracture per 1,000 person-years were 47.5 in HF cases and 30.4 in controls ( P =0.001). After adjustment for prior fracture and Charlson comorbidity score, the hazard ratio (HR) for fracture in HF cases vs. controls was 1.70 (95% CI: 1.17-2.47). β-blockers were prescribed in 45% of HF cases after diagnosis. The association between HF and fractures differed according to β-blocker usage. The HRs were 1.45 (95% CI: 0.86-2.47) and 2.16 (95% CI: 1.23-3.79) in HF cases prescribed and not prescribed β-blockers, respectively, when compared with their matched controls. Accounting for death as a competing risk, the HRs were 1.06 (95% CI: 0.64-1.76) and 1.63 (95% CI: 0.99-2.70) in HF cases on and off β-blockers, respectively. Conclusion: These findings suggest a modifying effect of β-blockers on the association between HF and osteoporotic fractures, which warrants a more thorough evaluation.
Abstract 18353: The Comparative Safety and Effectiveness of the Oral Anticoagulant (OAC) Dabigatran versus Warfarin Utilized in a Large Healthcare System in Non-valvular Atrial Fibrillation (NVAF) Patients
Authors: Todd C Villines, Janet Schnee, Kathy Fraeman, Kimberly Siu, Matthew W Reynolds, Jenna Collins, Eric Schwartzman
Journal: Circulation (2014)

Objectives: This study evaluated the safety and effectiveness of dabigatran versus warfarin for stroke risk reduction in NVAF patients in routine clinical care using the Department of Defense Military Health System database. Methods: In this retrospective cohort study, patients were included if they had an AF diagnosis within 12 months prior to first OAC treatment, were 18-89 years, and had a first prescription claim for either dabigatran or warfarin between 01-Oct-2010 and 31-Jul-2012 (index date). Patients were excluded if they had heart valve disorders or prosthetic heart valves, transient causes of AF, or any OAC use during the baseline period. Patients were censored when their prescriptions exceeded a 30 day allowable gap, at OAC switch, at disenrollment, at death, or at study end. A total of 14,813 dabigatran and 24,500 warfarin patients were available for propensity score matching (PSM). PSM based on baseline demographics and clinical characteristics was achieved 1:1 with 12,793 matched subjects per group (within a 0.20 caliper of standard deviation). Comparisons of safety and effectiveness outcomes were made based on Cox-proportional hazards models of PSM groups. All FDA-approved dosages were included in this analysis. Results: Results are summarized in Table 1. Conclusions: Hazard ratios in the post-PSM dabigatran cohort suggest that there is a lower likelihood for stroke, hemorrhagic stroke, major intracranial bleeding, major urogenital and other bleeding, MI, and death than in the warfarin cohort. The hazard ratio in the post-PSM dabigatran cohort suggests a higher likelihood for major lower GI bleeding, but a lower likelihood for intracranial, urogenital, and other bleeding than seen with warfarin. These results are generally consistent with findings of the randomized controlled clinical trial, RE-LY, and support that the benefits of dabigatran demonstrated in clinical trials also may be achieved in a broad population receiving routine clinical care.
Effect of Rotational Atherectomy in Noncalcified Atherosclerotic Plaque: A Volumetric Intravascular Ultrasound Study11This study was supported in part by the Cardiology Research Foundation, Washington, D.C., and by Heart Technology, Inc., Redmond, Washington.
Authors: GASTON R. DUSSAILLANT, GARY S. MINTZ, AUGUSTO D. PICHARD, KENNETH M. KENT, LOWELL F. SATLER, JEFFREY J. POPMA, MARTIN B. LEON
Journal: Journal of the American College of Cardiology (1996)
Abstract 1640: A novel small molecule inhibitor of lysophosphatidic acid acyltransferase-beta inhibits pancreatic cancer cell proliferation and mTOR signaling
Authors: Michelle A. Blaskovich, Yunting Luo, Yiyu Ge, Saïd M. Sebti, Harshani R. Lawrence, Nicholas J. Lawrence, Gregory M. Springett
Journal: Cancer Research (2014)

Abstract Lysophosphatidic acid acyltransferase (LPAAT-β), a phosphatidic acid (PA)-generating enzyme, plays an essential role in triglyceride synthesis. A less familiar role for LPAAT-β is that of a regulator of cell growth and differentiation by means of the function of its product, PA, which plays a vital role in the activation of key signal transduction proteins including Raf, PKC-ζ and mTOR. It is in this role that LPAAT-β presents as a potential therapeutic target in cancer. Accordingly, we developed a library of small molecule inhibitors of LPAAT-β with nanomolar activity against LPAAT-β enzyme activity in vitro (2012 Annual Meeting, Abstract #2470). We have now performed additional SAR and lead optimization to produce a potent small molecule that inhibits proliferation, mTOR signaling pathways, and total cellular PA levels at low micromolar concentrations. The lead compound also inhibits anchorage-independent growth of pancreatic cancer cell lines at nanomolar concentrations. This compound demonstrates effects on cellular signaling that are similar to the effects of LPAAT-β siRNA. Citation Format: Michelle A. Blaskovich, Yunting Luo, Yiyu Ge, Saïd M. Sebti, Harshani R. Lawrence, Nicholas J. Lawrence, Gregory M. Springett. A novel small molecule inhibitor of lysophosphatidic acid acyltransferase-beta inhibits pancreatic cancer cell proliferation and mTOR signaling. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1640. doi:10.1158/1538-7445.AM2014-1640
Recent Advances in Sex and Reproductive Physiology
Authors: John Michael Robson
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Integrating ethics and science in the International HapMap Project
Authors: Morris W. Foster
Journal: Nature Reviews Genetics (2004)

Genomics resources that use samples from identified populations raise scientific, social and ethical issues that are, in many ways, inextricably linked. Scientific decisions about which populations to sample to produce the HapMap, an international genetic variation resource, have raised questions about the relationships between the social identities used to recruit participants and the biological findings of studies that will use the HapMap. The sometimes problematic implications of those complex relationships have led to questions about how to conduct genetic variation research that uses identified populations in an ethical way, including how to involve members of a population in evaluating the risks and benefits posed for everyone who shares that identity. The ways in which these issues are linked is increasingly drawing the scientific and ethical spheres of genomics research closer together.
Abstract OT1-1-06: A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)
Authors: Miguel Martin, Manuel Ruiz-Borrego, José M Trigo, Silvia Antolin, Jose A Garcia-Saenz, Andres Hernando, Alberto Ocaña, Federico Rojo, Sara Lopez-Tarruella, Jesus Corral, Nuria Ribelles, Lourdes Calvo, Fernando Moreno, Rosalia Caballero, Eva Carrasco
Journal: Cancer Research (2015)

Abstract Background: LDE225 is a potent and selective oral inhibitor of Smo, a key component of the hedgehog (Hh) signaling pathway. Up-regulation of the Hh pathway is implicated in the genesis of a wide range of tumors including triple negative breast cancer. Here we report an ongoing phase I study exploring the combination of LDE225 with docetaxel in TN ABC patients to identify the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) (ClinicalTrials.gov Identifier: NCT02027376). Trial Design: Eligibility criteria include patients with TN ABC candidates to receive treatment with docetaxel that have received a maximum of 3 prior chemotherapy regimens. Those patients with CNS involvement are also candidates if treated and clinically stable. Treatment consists of 21-day cycles with docetaxel 75mg/m2 on day 1, every 21 day and LDE225 once daily. We use a standard 3+3 design in sequential cohorts (3 dose levels (DL) of LDE225: 400mg once daily (DL1), 600mg once daily (DL2), 800mg once daily (DL3); and a DL-1: LDE225 400mg once daily and docetaxel 60mg/m2 every three weeks). The primary endpoint is the MTD and RP2D of the combination; secondary endpoints include evaluation of safety and tolerability, in addition to pharmacodynamic (PD) and pharmacokinetic (PK) studies. Patients are treated until radiologic or symptomatic progression or unacceptable toxicity occurs. PK will be performed to evaluate whether LDE225 influences the pharmacology of docetaxel. PD assessments include Hg gene expression signature associated to pathway activation in tumor samples and changes in Smo related biomarkers in skin and blood correlative samples. Efficacy will be measured in terms of time to progression and objective response rate. A minimum of 9 and a maximum of 18 patients will be included in this phase I. The study is approved by ERBs and Competent Authority and already recruiting patients (two patients included in DL1). Citation Format: Miguel Martin, Manuel Ruiz-Borrego, José M Trigo, Silvia Antolin, Jose A Garcia-Saenz, Andres Hernando, Alberto Ocaña, Federico Rojo, Sara Lopez-Tarruella, Jesus Corral, Nuria Ribelles, Lourdes Calvo, Fernando Moreno, Rosalia Caballero, Eva Carrasco. A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT1-1-06.
Thumbs Up for PCSK9 Inhibitors
Authors: Rebecca Voelker
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2437: Atrial Fibrillation Ablation in Patients with Therapeutic INRs: Comparison of Strategies of Anticoagulation Management in the Periprocedure Period
Authors: Oussama M Wazni, Salwa Salwa Beheiry, Steven Hao, Richard Hongo, Mohammad Kanj, Robert Schweikert, Mauricio Arruda, David O Martin, Walid Saliba, Andrea Natale
Journal: Circulation (2007)

Introduction : Management of anticoagulation peri-pulmonary vein isolation (PVI) to cure atrial fibrillation is necessary to prevent thromboembolism while avoiding complications from anticoagulation. The best approach to management of anticoagulation around the AF ablation is not known. Methods: We compared outcomes in consecutive patients undergoing PVI for chronic AF. Initially coumadin was stopped 3 days before ablation and a TEE was performed to rule out clot. Enoxaparin, initially 1mg/kg twice daily (Group1) and then 0.5mg/kg twice daily (Group 2) was used to bridge patients after ablation. Subsequently,Group 3 patients were kept on warfarin keeping the INR between 2–3. Heparin bolus (100 –150 units/kg) was given before trans-septal punctures. The infusion rate was adjusted to keep the activated clotting time in the range of 350 to 450 seconds. Minor bleeding was defined as hematoma not requiring intervention. Major bleeding was defined as either cardiac tamponade, hematoma requiring intervention or bleeding requiring blood transfusion. Results (Table ): PVI was performed in 355 patients (Group 1±105, Group 2±100, Group 3±150. More patients had spontaneous echo contrast in groups 1 and 2. In group 1 one patient had an ischemic stroke vs. 2 patients in group 2 and no patients in group 3. In group 1 there were 13 patients with minor bleeding and 9 patients with major bleeding. In group 2 19 patients had minor bleeding and 2 patients developed pericardial effusion with no tamponade. In group 3 eight patients developed minor hematoma and no major bleeding. Conclusion : This present study shows that continuation of warfarin through PVAI without the need for administration of enoxaparin pre and post PVI is safe and efficacious. Utilization of this strategy can prevent suboptimal anticoagulation that may increase the risk for stroke and eliminates the need for enoxaparin that is associated with more bleeding and is costly and inconvenient. Patient Characteristics and Results
Functional Somatic Syndromes
Authors: James McSherry
Journal: Annals of Internal Medicine (2000)

Letters15 February 2000Functional Somatic SyndromesJames McSherry, MB, ChBJames McSherry, MB, ChBUniversity of Western Ontario; London, Ontario N5X 2C1, Canada (McSherry)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-4-200002150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Barsky and Borus (1) have given us an erudite and elegant article on functional somatic syndromes. They proffer cogent arguments against an organic basis for a variety of clinical syndromes, including candidiasis, hypoglycemia via the sick building syndrome, and mitral valve prolapse. I agree that patients become trapped in a “sick role” when the continuation of benefits depends on symptom persistence and that the adversarial nature of claiming sickness benefits inhibits recovery by reinforcing the severity of disability.I'm less impressed with their argument that certain conditions are less common when they are not covered by health ...Reference1. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130:910-21. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Western Ontario; London, Ontario N5X 2C1, Canada (McSherry) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFunctional Somatic Syndromes Arthur J. Barsky and Jonathan F. Borus Functional Somatic Syndromes Kenneth Clemenger Functional Somatic Syndromes Allan Clemenger Functional Somatic Syndromes Ellen Goudsmit Functional Somatic Syndromes Melody Heard Functional Somatic Syndromes Frank Albrecht Functional Somatic Syndromes Thomas L. English Functional Somatic Syndromes Thomas L. Kurt Functional Somatic Syndromes Arthur J. Barsky and Jonathan F. Borus Functional Somatic Syndromes Terry E. Hedrick Metrics 15 February 2000Volume 132, Issue 4Page: 327KeywordsBehaviorCandidiasisDisabilitiesHealth insuranceHealth statisticsHypoglycemiaMitral valve prolapseQuality of life ePublished: 15 August 2000 Issue Published: 15 February 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THE ELECTROCARDIOGRAM IN ALKALOSIS
Authors: Lewis W. Woodruff
Journal: Annals of Internal Medicine (1950)

Case Reports1 March 1950THE ELECTROCARDIOGRAM IN ALKALOSISLEWIS W. WOODRUFF, M.D., F.A.C.P.LEWIS W. WOODRUFF, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-3-562 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBecause of the infrequent opportunity to observe the striking, transient changes in the electrocardiogram of patients with severe alkalosis, the following case history with electrocardiograms during, and after recovery from, severe alkalosis is presented.CASE REPORTThe patient was a 58 year old prison guard, who was admitted to the hospital on April 13, 1947, because of profound weakness, attacks of fainting, nausea, and mental confusion.The history began in 1937, when he first had upper abdominal pain of a colicky type, several hours after meals relieved by taking food. In 1941 he had a severe hemorrhage with markedly tarry...Bibliography1. LawrenceAllott JSEN: Heart changes in alkalosis, Brit. Heart J. 5: 128-130, 1943. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Joliet, Illinois*Received for publication December 26, 1947. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMetalle 1 March 1950Volume 32, Issue 3Page: 562-565KeywordsAbdominal painElectrocardiographyFoodHemorrhageNauseaSyncope Issue Published: 1 March 1950 PDF downloadLoading ...